Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Susan Spratt"


4 mentions found


Less than a fifth of large companies in the United States include coverage for the popular but pricey weight loss drugs Wegovy and Zepbound in their health insurance plans, according to a survey published Wednesday in Health Affairs. “They’re trying to figure out what is the right balance between the advantages to employees, potential health benefits and the cost of these drugs. The survey found that about half of employers that cover the weight loss drugs have certain requirements associated with their coverage, which Rae said would limit access for some employees but save money. Among large firms that don’t currently cover GLP-1 drugs for weight loss, only about 3% said they’re “very likely” to do so in the next year. Despite the exorbitant cost, employers do have a positive view of the drugs.
Persons: Wegovy, , Matthew Rae, “ They’re, , Rae, Susan Spratt, Christopher McGowan, Eli Lilly, ” McGowan, , ” Rae, you’ve, that’s, don’t, they’re Organizations: Health Affairs, “ Employers, Population Health Management, Duke Health, Centers for Disease Control, Novo Nordisk, Research, North Carolina, ” Novo Nordisk Locations: United States, KFF, North Carolina, U.S, Novo
The rate of weight loss with the experimental pill, called amycretin, appears to be more rapid than what’s seen for other drugs. “It’s roughly double the weight loss rate seen with current GLP-1 agonists and approaching procedural or surgical-level outcomes,” said Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in North Carolina. McGowan said that while the weight loss was significant, he still has concerns about how fast people lost weight. “While losing weight is seemingly the end goal, how that weight is lost matters,” he said. Spratt said she would like to know how much of the weight loss came from fat compared with muscle.
Persons: , , Christopher McGowan, ” Dr, Susan Spratt, Spratt, haven’t, Martin Lange, Lange, McGowan, ” McGowan Organizations: Novo Nordisk, European Association for, Diabetes, Population Health Management, Duke Health Locations: Novo, Spain, North Carolina, semaglutide, Wegovy, It’s
She didn't find success until her doctor prescribed Wegovy, a weight loss drug, in August 2021. But it all stopped in February, when Bayandor's health insurance denied her coverage, forcing her to stop taking the medication. Artemis BayandorBayandor's experience isn't uncommon: Widespread shortages of Wegovy, a popular weight loss aid, have forced some people in the U.S. to stop taking it, leading them to gain some — or all — of their weight back. "When you're at that max weight loss, your body's hunger hormones are the highest," she said. In May, an unrelated thyroid issue landed her in the hospital and forced her to stop taking Wegovy.
For the past two years, she's managed the condition using a drug called Ozempic, which helps people with diabetes keep blood sugar levels in check. "It's been very frustrating," Largent-Phillips, of Florida, said of the shortage, adding that her blood sugar levels have been fluctuating as she's had to change medications. If the body doesn't use it well, that sugar stays in the blood, resulting in high blood sugar levels. His wife, Gerilynn, who is a nurse, said his blood sugar levels have gone back up since being off Ozempic. Largent-Phillips, of Florida — who has been documenting her experience on TikTok — said that for now, she has to be vigilant about monitoring her blood sugar levels.
Total: 4